European CRO Nuvisan Group to take over part Galderma’s R&D
The European contract research organization (CRO) Nuvisan Group set a public goal to grow as an early stage drug development company and will work towards that goal through an agreement it signed with Nestle Skin Health’s medical solutions business Galderma.
The agreement will give research and development (R&D) capacities at Galderma’s facility in Sophia Antipolis, France.
According to Galderma the facility is the largest R&D facility in the world focused on medical and cosmetic skin solutions. The center was opened in 2006 by Galderma.
Nuvisan will be able to grow its service lines in bioanalysis, clinical trial supplies, and pharmaceutical analytics from this agreement. The company also will be adding GMP-API synthesis formulation capabilities for prescription drugs and cosmetics.
Per the agreement, Nuvisan will continue its goal for growth as Galderma will add 80 employees to Nuvisan’s existing 325.
Nuvisan also will extend its knowledge to fields beyond skin health. The additional R&D capacity will allow the company to grow in chemistry, liquid and semi-solid formulation development, and create a center that is more centrally located for European customers, according to Nuvisan.
The agreement has been signed and Nuvisan’s operations at the Sophia Antipolis site will begin in October of 2018.
